Literature DB >> 2930809

Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol abnormalities in depression.

R E Poland1, L Tondo, R T Rubin, R B Trelease, I M Lesser.   

Abstract

Scopolamine (SCOP) (3.0 mu/kg and 6.0 micrograms/kg) and saline were administered intramuscularly at 11:00 PM to eight normal male volunteers in a randomized design, and the effects on the sleep electroencephalogram (EEG) and nocturnal cortisol secretion (via blood sampling every 15 min) were evaluated. Compared to saline, SCOP produced a significant dose-related delay in rapid eye movement (REM) latency. In contrast, neither dose of SCOP significantly affected nocturnal plasma cortisol concentrations. These results suggest that the central cholinergic system that regulates the onset of REM sleep is more sensitive to dysregulation than the cholinergic system that controls the degree of nocturnal cortisol secretion. If central cholinergic overactivity is responsible for both the REM sleep latency and cortisol abnormalities in depressed patients, then our findings with SCOP might help explain why the incidences of these abnormalities are different.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930809     DOI: 10.1016/0006-3223(89)90193-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Cholinergic neurotransmission seems not to be involved in depression but possibly in personality.

Authors:  J Fritze; M Lanczik; E Sofic; M Struck; P Riederer
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 2.  FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Authors:  Ahmad I Antar; Zaher K Otrock; Elias Jabbour; Mohamad Mohty; Ali Bazarbachi
Journal:  Leukemia       Date:  2020-01-09       Impact factor: 11.528

Review 3.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

4.  Electroencephalographic sleep and hypothalamic-pituitary-adrenal changes from episode to recovery in depressed adolescents.

Authors:  Uma Rao; Russell E Poland
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-12       Impact factor: 2.576

5.  Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers.

Authors:  Konstanze Diefenbach; Frank Donath; Agathe Maurer; Sabine Quispe Bravo; Klaus-Dieter Wernecke; Ulrich Schwantes; Jutta Haselmann; Ivar Roots
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 6.  The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Authors:  Won Je Jeon; Brian Dean; Elizabeth Scarr; Andrew Gibbons
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.